- Home
- JAGU vs CNTX Comparison
JAGU vs CNTX Comparison
Compare JAGU & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAGU | CNTX |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | Canada | United States |
| Employees | 3 | 15 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.2M | 51.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JAGU | CNTX |
|---|---|---|
| Price | $1.61 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 130.0K | ★ 2.7M |
| Earning Date | 03-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $0.55 |
| 52 Week High | $3.60 | $3.62 |
Technical Indicators
Market Signals| Indicator | JAGU | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 20.39 |
| Support Level | $1.58 | N/A |
| Resistance Level | $2.27 | $1.30 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 33.54 | 3.80 |
Price Performance
Historical ComparisonAbout JAGU Jaguar Uranium Corp. Class A Common Shares
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.